Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

@article{Hedlund2008ParenteralEV,
  title={Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5},
  author={Per Olov Hedlund and J. Damber and I. Hagerman and S. Haukaas and P. Henriksson and P. Iversen and R. Johansson and P. Klarskov and F. Lundbeck and F. Rasmussen and E. Varenhorst and J. Viitanen},
  journal={Scandinavian Journal of Urology and Nephrology},
  year={2008},
  volume={42},
  pages={220 - 229}
}
Objective. To compare parenteral estrogen therapy in the form of high-dose polyestradiol phosphate (PEP; Estradurin®) with combined androgen deprivation (CAD) in the treatment of prostate cancer patients with skeletal metastases. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular events. Material and methods. In total, 910 eligible patients with T0–4, NX, M1, G1–3 prostate cancer with an Eastern Cooperative Oncology Group performance status of… Expand
Androgen Deprivation Therapy in Prostate Cancer - Current Status in M1 Patients
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
Estrogens in the treatment of prostate cancer.
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
  • Medicine
  • The New England journal of medicine
  • 1984
Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate
The Importance of Prognostic Factors in Advanced Prostate Cancer
...
1
2
3
4
5
...